This week, the ratings of four biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Amarin Corporation Plc Sponsored ADR (AMRN) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Portfolio Grader’s specific subcategory of Cash Flow, AMRN also gets an F. As of Jan. 29, 2014, 14.8% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
This week, Trius Therapeutics, Inc. (TSRX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
Nymox Pharmaceutical Corporation (NYMX) experiences a ratings drop this week, going from last week’s C to a D. Nymox Pharmaceutical is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. For more information, get Portfolio Grader’s complete analysis of NYMX stock.
This week, Discovery Laboratories, Inc.’s (DSCO) rating worsens to a D from the company’s C rating a week ago. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
